Summary by Futu AI
Hua Ling Pharmaceuticals-B (Stock Code: 02552.HK) submitted the latest monthly securities report to the Hong Kong Exchanges and Clearing Limited on September 4, 2024, reporting the changes in the company's share capital as of August 31, 2024. The report indicated that there were no changes in the statutory/registered share capital and the number of shares issued by Hua Ling Pharmaceuticals in August. The statutory/registered number of ordinary shares remained at 2,000,000,000 shares with a face value of 0.001 USD, and the number of issued shares (excluding treasury shares) remained at 1,055,588,761 shares. In addition, the company's stock options plan did not have any new issuances this month, but 31,658 stock options expired, resulting in a slight decrease in the number of stock options held at the end of the month to 52,799,265 shares. The company confirmed that all issuances of securities or sales and transfers of treasury shares have been authorized by the board of directors and are in compliance with relevant listing rules and legal regulations.
